Non-surgical interventions for threatened and recurrent miscarriages

Singapore Medical Journal

Volumn 48, Issue 12, 2007, Pages 1074-1090

  Tien, J C ^a   Tan, Tony Y T ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b RAFFLES HOSPITAL   (Singapore)

Author keywords

Human chorionic gonadotrophin; Miscarriage; Prospective miscarriage risk; Recurrent miscarriage; Threatened miscarriage

Indexed keywords

ACETYLSALICYLIC ACID; BROMOCRIPTINE; CHORIONIC GONADOTROPIN; CLINDAMYCIN; CLOMIFENE CITRATE; DYDROGESTERONE; ENOXAPARIN; HEPARIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROGESTERONE; VITAMIN;

ALCOHOL CONSUMPTION; ANTIPHOSPHOLIPID SYNDROME; BED REST; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DEPENDENCE; DRUG EXPOSURE; FETUS WASTAGE; FRACTURE; GESTATIONAL AGE; HEALTH HAZARD; HORMONE RELEASE; HUMAN; HYPERPROLACTINEMIA; IMMINENT ABORTION; IMMUNOTHERAPY; INFERTILITY; META ANALYSIS; MONOTHERAPY; OSTEOPENIA; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PARENTAL AGE; PATIENT CARE; PREGNANCY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL INTERCOURSE; SMOKING; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOPHILIA; UTERUS MALFORMATION; VAGINITIS; EVIDENCE BASED MEDICINE; FEMALE; INCIDENCE; MEDICAL EDUCATION; METHODOLOGY; MONITORING; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; RECURRENT ABORTION; RISK ASSESSMENT; SINGAPORE;

ABORTION, HABITUAL; ABORTION, THREATENED; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; BED REST; CHORIONIC GONADOTROPIN; EDUCATION, MEDICAL, CONTINUING; EVIDENCE-BASED MEDICINE; FEMALE; GESTATIONAL AGE; HEPARIN; HUMANS; INCIDENCE; METFORMIN; MONITORING, PHYSIOLOGIC; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SINGAPORE;

EID: 38449090777     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997; 315:32-4.
2. Bulletti C, Flamigni C, Giacomucci E. Reproductive failure due to spontaneous abortion and recurrent miscarriage. Hum Reprod Update 1996; 2:118-36.
3. Huisjes HJ, Lind T. Early Pregnancy Failure. Edinburgh: Churchill Livingstone, 1990.
4. Whittaker PG, Taylor A, Lind T. Unsuspected pregnancy loss in healthy women. Lancet 1983; 1:1126-7.
5. Weiss JL, Malone FD, Vidaver J, et al. Threatened abortion: A risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 2004; 190:745-50.
6. Porter TF, Scott JR. Evidence-based care of recurrent miscarriage. Best Pract Res Clin Obstet Gynaecol 2005; 19:85-101.
7. Christiansen OB, Nybo Andersen AM, Bosch E, et al. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril 2005; 83: 821-39.
8. Hogge WA, Byrnes AL, Lanasa MC, Surti U. The clinical use of karyotyping spontaneous abortions. Am J Obstet Gynecol 2003; 189:397-400.
9. Greene MF, Hare JW, Cloherty JP, Benacerraf BR, Soeldner JS. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology 1989; 39:225-31.
10. Stagnaro-Green A, Roman SH, Cobin RH, et al. Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA 1990; 264:1422-5.
11. Imbasciati E, Surian M, Bottino S, et al. Lupus nephropathy and pregnancy. A study of 26 pregnancies in patients with systemic lupus erythematosus and nephritis. Nephron 1984; 36:46-51.
12. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301-4.
13. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 2003; 327:368.
14. Lin PC. Reproductive outcomes in women with uterine anomalies. J Womens Health (Larchmt) 2004;13:33-9.
15. Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol 1984; 148:140-6.
16. Hay PE, Lamont RF, Taylor-Robinson D, et al. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ 1994; 308:295-8.
17. Sarig G, Younis JS, Hoffman R, et al. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002; 77:342-7.
18. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87:489-93.
19. Habayeb OM, Konje JC. The one-stop recurrent miscarriage clinic: an evaluation of its effectiveness and outcome. Hum Reprod 2004; 19:2952-8.
20. Risch HA, Weiss NS, Clarke EA, Miller AB. Risk factors for spontaneous abortion and its recurrence. Am J Epidemiol 1988; 128:420-30.
21. Kleinhaus K, Perrin M, Friedlander Y, et al. Paternal age and spontaneous abortion. Obstet Gynecol 2006; 108:369-77.
22. Slama R, Bouyer J, Windham G, et al. Influence of paternal age on the risk of spontaneous abortion. Am J Epidemiol 2005; 161:816-23.
23. Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989; 299:541-5.
24. Pandey MK, Thakur S, Agrawal S. Lymphocyte immunotherapy and its probable mechanism in the maintenance of pregnancy in women with recurrent spontaneous abortion. Arch Gynecol Obstet 2004; 269:161-72.
25. Warburton D, Fraser FC. On the probability that a woman who has had a spontaneous abortion will abort in subsequent pregnancies. J Obstet Gynaecol Br Emp 1961; 68:784-8.
26. Cotzias CS, Paterson-Brown S, Fisk NM. Prospective risk of unexplained stillbirth in singleton pregnancies at term: population based analysis. BMJ 1999; 319:287-8.
27. Feldman GB. Prospective risk of stillbirth. Obstet Gynecol 1992; 79:547-53.
28. Hoey R, Allan K. Does speculum examination have a role in assessing bleeding in early pregnancy? Emerg Med J 2004; 21:461-3.
29. Basama FM, Crosfill F. The outcome of pregnancies in 182 women with threatened miscarriage. Arch Gynecol Obstet 2004; 270:86-90.
30. Johns J, Jauniaux E. Threatened miscarriage as a predictor of obstetric outcome. Obstet Gynecol 2006; 107:845-50.
31. Rust OA, Atlas RO, Jones KJ, Benham BN, Balducci J. A randomized trial of cerclage versus no cerclage among patients with ultrasonographically detected second-trimester preterm dilatation of the internal os. Am J Obstet Gynecol 2000; 183:830-5.
32. Novy MJ, Gupta A, Wothe DD, et al. Cervical cerclage in the second trimester of pregnancy: a historical cohort study. Am J Obstet Gynecol 2001; 184:1447-54.
33. Devi Wold AS, Pham N, Arici A. Anatomic factors in recurrent pregnancy loss. Semin Reprod Med 2006; 24:25-32.
34. Bamigboye AA, Morris J. Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes. Cochrane Database Syst Rev 2003; CD004271.
35. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005; CD002859.
36. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119(1 Suppl):122S-31S.
37. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668-72.
38. Keim SA, Klebanoff MA. Aspirin use and miscarriage risk. Epidemiology 2006; 17:435-9.
39. Kozer E, Costei AM, Boskovic R, et al. Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol 2003; 68:70-84.
40. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994;120:470-5.
41. Di Simone N, Raschi E, Testoni C, et al. Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. Ann Rheum Dis 2005; 64:462-7.
42. Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998; 352:1037-8.
43. Di Simone N, Caliandro D, Castellani R, et al. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod 1999; 14:489-95.
44. Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183:1008-12.
45. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361:901-8.
46. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1:433-8.
47. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103:3695-9.
48. Brenner B, Bar J, Ellis M, et al. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study. Fertil Steril 2005; 84:770-3.
49. The investigation and treatment of couples with recurrent miscarriage. Royal College of Obstetricians and Gynaecologists, 2003. Available at: www.rcog.org.uk/resources/Public/pdf/Recurrent_Miscarriage_No17.pdf. Accessed October 19, 2006.
50. ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 78:179-90.
51. Summary Statement on the investigation and treatment of couples with recurrent pregnancy loss. College of Obstetricians and Gynaecologists, Singapore, 2006. Available at: www.ams.edu.sg/chapters/PDF/ Couples_with_Recurrent_Pregnancy_Loss.pdf. Accessed October 19, 2006.
52. Nelson DB, Macones G. Bacterial vaginosis in pregnancy: current findings and future directions. Epidemiol Rev 2002; 24:102-8.
53. McGregor JA, French JI, Parker R, et al. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. Am J Obstet Gynecol 1995; 173:157-67.
54. Ralph SG, Rutherford AJ, Wilson JD. Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study. BMJ 1999; 319:220-3.
55. Oakeshott P, Hay P, Hay S, et al. Association between bacterial vaginosis or chlamydial infection and miscarriage before 16 weeks' gestation: prospective community based cohort study. BMJ 2002; 325:1334.
56. McDonald H, Brocklehurst P, Parsons J. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2005; CD000262.
57. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003; 361:983-8.
58. Larsson PG, Fahraeus L, Carlsson B, et al. Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen. BJOG 2006; 113:629-37.
59. Petrou S, Mehta Z, Hockley C, et al. The impact of preterm birth on hospital inpatient admissions and costs during the first 5 years of life. Pediatrics 2003; 112:1290-7.
60. Klebanoff MA, Hauth JC, MacPherson CA, et al. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. Am J Obstet Gynecol 2004; 190:363-70.
61. Gratacós E, Figueras F, Barranco M, et al. Spontaneous recovery of bacterial vaginosis during pregnancy is not associated with an improved perinatal outcome. Acta Obstet Gynecol Scand 1998; 77:37-40.
62. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
63. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87:524-9.
64. Liddell HS, Sowden K, Farquhar CM. Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome. Aust N Z J Obstet Gynaecol 1997; 37:402-6.
65. Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 1994; 9:1328-32.
66. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17:2858-64.
67. Thatcher SS, Jackson EM. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril 2006; 85:1002-9.
68. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75:46-52.
69. Micromedex healthcare series. Micromedex. Available at: www.thomsonhc.com/home/dispatch. Accessed June 20, 2006.
70. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006; 86:658-63.
71. Bussen S, Sütterlin M, Steck T. Endocrine abnormalities during the follicular phase in women with recurrent spontaneous abortion. Hum Reprod 1999; 14:18-20.
72. Li TC, Spuijbroek MD, Tuckerman E, et al. Endocrinological and endometrial factors in recurrent miscarriage. BJOG 2000; 107:1471-9.
73. Hirahara F, Andoh N, Sawai K, et al. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril 1998; 70:246-52.
74. Dlugi AM. Hyperprolactinemic recurrent spontaneous pregnancy loss: a true clinical entity or a spurious finding? Fertil Steril 1998; 70:253-5.
75. Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 1990; 336:1141-4.
76. Nardo LG, Rai R, Backos M, El-Gaddal S, Regan L. High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril 2002; 77:348-52.
77. Johnson P, Pearce JM. Recurrent spontaneous abortion and polycystic ovarian disease: comparison of two regimens to induce ovulation. BMJ 1990; 300:154-6.
78. Clifford K, Rai R, Watson H, Franks S, Regan L. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. BMJ 1996; 312:1508-11.
79. Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997; 12:387-9.
80. Liddell HS, Pattison NS, Zanderigo A. Recurrent miscarriage - outcome after supportive care in early pregnancy. Aust N Z J Obstet Gynaecol 1991; 31:320-2.
81. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br J Obstet Gynaecol 1989; 96:275-80.
82. Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973; 115:759-65.
83. Jones GE. Some newer aspects of the management of infertility. J Am Med Assoc 1949; 141:1123-9.
84. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol 1975; 122:262-3.
85. Tulppala M, Björses UM, Stenman UH, Wahlström T, Ylikorkala O. Luteal phase defect in habitual abortion: progesterone in saliva. Fertil Steril 1991; 56:41-4.
86. Wentz AC. Endometrial biopsy in the evaluation of infertility. Fertil Steril 1980; 33:121-4.
87. Davis OK, Berkeley AS, Naus GJ, Cholst IN, Freedman KS. The incidence of luteal phase defect in normal, fertile women, determined by serial endometrial biopsies. Fertil Steril 1989; 51:582-6.
88. Bukulmez O, Arici A. Luteal phase defect: myth or reality. Obstet Gynecol Clin North Am 2004; 31:727-44, ix.
89. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989; 96:265-74.
90. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990; 97:149-54.
91. Moller K, Fuchs F. Double-blind controlled trial of 6-methyl-17- acetoxyprogesterone in threatened abortion. J Obstet Gynaecol Br Commonw 1965; 72:1042-4.
92. Limbeck GA, Ruvalcaba RH, Kelley VC. Simulated congenital adrenal hyperplasia in a male neonate associated with medroxyprogesterone therapy during pregnancy. Am J Obstet Gynecol 1969; 103:1169-70.
93. Katz Z, Lancet M, Skornik J, et al. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 1985; 65:775-80.
94. Yovich JL, Turner SR, Draper R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 1988; 38:135-44.
95. Shearman RP. Hormonal treatment of habitual abortion. In: Behrman SJ, Kistner RW, eds. Progress in Infertility. London: V&A Churchill, 1968:767-7.
96. Yemini M, Borenstein R, Dreazen E, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 1985; 151:574-7.
97. Levine L. Habitual abortion. A controlled study of progestational therapy. West J Surg Obstet Gynecol 1964; 72:30-6.
98. Johnson JW, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975; 293:675-80.
99. Reijnders FJ, Thomas CM, Doesburg WH, Rolland R, Eskes TK. Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial. Br J Obstet Gynaecol 1988; 95:462-8.
100. Oates-Whitehead RM, Haas DM, Carrier JA. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2003; CD003511.
101. Demirkiran M, Aslan K, Bicakci S, Bozdemir H, Ozeren A. Transient parkinsonism: induced by progesterone or pregnancy? Mov Disord 2004; 19:1382-4.
102. Lanzetta P, Crovato S, Pirracchio A, Bandello F. Retinal arteriolar obstruction with progestogen treatment of threatened abortion. Acta Ophthalmol Scand 2002; 80:667-8.
103. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348:2379-85.
104. Roberts IF, West RJ. Teratogenesis and maternal progesterone. Lancet 1977; 2:982.
105. Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 2005; 97:421-5.
106. El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 2005; 97:431-4.
107. Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B. Double-blind controlled trial of progesterone substitution in threatened abortion. Biol Res Pregnancy Perinatol 1987; 8:26-34.
108. Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod 2002; 17:357-61.
109. Swyer GI, Daley D. Progesterone implantation in habitual abortion. Br Med J 1953; 1:1073-7.
110. Vignali M, Centinaio G. [Efficacy of the vaginal administration of natural progesterone in patients with recurrent spontaneous hormone caused abortion]. Minerva Ginecol 2000; 52:367-74. Italian.
111. Everett C, Ashurst H, Chalmers I. Reported management of threatened miscarriage by general practitioners in Wessex. Br Med J (Clin Res Ed) 1987; 295:583-6.
112. Läpple M. [Occupational factors in spontaneous abortion]. Zentralbl Gynakol 1990; 112:457-66. German.
113. Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol 2000; 182:1089-92.
114. Maloni JA, Chance B, Zhang C, et al. Physical and psychosocial side effects of antepartum hospital bed rest. Nurs Res 1993; 42:197-203.
115. Maloni JA, Brezinski-Tomasi JE, Johnson LA. Antepartum bed rest: effect upon the family. J Obstet Gynecol Neonatal Nurs 2001; 30:165-73.
116. Aleman A, Althabe F, Belizán J, Bergel E. Bed rest during pregnancy for preventing miscarriage. Cochrane Database Syst Rev 2005; CD003576.
117. Hamilton RA, Grant AM, Henry OA, Eldurrija SM, Martin DH. The management of bleeding in early pregnancy. Ir Med J 1991; 84:18-9.
118. Harrison RF. A comparative study of human chorionic gonadotropin, placebo, and bed rest for women with early threatened abortion.Int J Fertil Menopausal Stud 1993; 38:160-5.
119. Giobbe M, Fazzio M, Boni T. [Current role of bed-rest in threatened abortion]. Minerva Ginecol 2001; 53:337-40. Italian.
120. Ben-Haroush A, Yogev Y, Mashiach R, Meizner I. Pregnancy outcome of threatened abortion with subchorionic hematoma: possible benefit of bed-rest? Isr Med Assoc J 2003; 5:422-4.
121. Brustman LE, Raptoulis M, Langer O, Anyaegbunam A, Merkatz IR. Changes in the pattern of uterine contractility in relationship to coitus during pregnancies at low and high risk for preterm labor. Obstet Gynecol 1989; 73:166-8.
122. Yost NP, Owen J, Berghella V, et al. Effect of coitus on recurrent preterm birth. Obstet Gynecol 2006; 107:793-7.
123. Di Cintio E, Parazzini F, Chatenoud L, et al. Dietary factors and risk of spontaneous abortion. Eur J Obstet Gynecol Reprod Biol 2001; 95:132-6.
124. Rumbold A, Middleton P, Crowther CA. Vitamin supplementation for preventing miscarriage. Cochrane Database Syst Rev 2005; CD004073.
125. Qureshi NS, Edi-Osagie EC, Ogbo V, Ray S, Hopkins RE. First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trial. BJOG 2005; 112:1536-41.
126. Harrison RF. Human chorionic gonadotrophin (hCG) in the management of recurrent abortion; results of a multi-centre placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 1992; 47:175-9.
127. Quenby S, Farquharson RG. Human chorionic gonadotropin supplementation in recurring pregnancy loss: a controlled trial. Fertil Steril 1994; 62:708-10.
128. Lede R, Duley L. Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database Syst Rev 2005; CD002857.
129. Ruppin E, Ruppin J, Chelius HH. [A double blind study of the treatment of threatened abortion with fenoterol hydrobromide (author's transl)]. Geburtshilfe Frauenheilkd 1981; 41:218-21. German.
130. Souka AR, Osman M, Sibaie F, Einen MA. Therapeutic value of indomethacin in threatened abortion. Prostaglandins 1980; 19:457-60.
131. Mowbray JF, Gibbings C, Liddell H, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet 1985; 1:941-3.
132. Porter T, Lacoursiere Y, Scott Jr. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2006; CD000112.
133. Daya S, Gunby J, Clark DA. Intravenous immunoglobulin therapy for recurrent spontaneous abortion: a meta-analysis. Am J Reprod Immunol 1998; 39:69-76.
134. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993; 9:254-62.